⚠️ Educational purposes only. PeptideIQ does not constitute medical advice, diagnosis, or treatment. Peptide therapy should only be pursued under the guidance of a licensed medical provider. Many peptides discussed are research-grade compounds not approved by the FDA. Always verify current legal status in your jurisdiction before use.
← Back to library
Tesamorelin
Tesamorelin (Egrifta)
Strong RCTFDA Approved
An FDA-approved GHRH analog originally for HIV-related lipodystrophy, now widely used for visceral fat reduction and body composition.
Mechanism of action
GHRH receptor agonism, GH stimulation, visceral fat reduction, IGF-1 elevation
Primary benefits
- ✓Visceral fat reduction
- ✓Lean muscle preservation
- ✓Improved body composition
- ✓Cognitive benefits
- ✓GH restoration
Dosing
Beginner
1 mg/day
Intermediate
1-2 mg/day
Advanced
2 mg/day
Frequency: Once daily
Timing: Pre-sleep fasted
Route: Subcutaneous injection
Cycling protocol
Duration
12-26 weeks
Pattern
Daily
Break after
4-8 weeks
Important warnings
- ⚠️FDA-approved for HIV lipodystrophy — off-label for general use
- ⚠️Prescription required
- ⚠️Monitor glucose levels